Home » Stocks » Adhera Therapeutics

Adhera Therapeutics, Inc. (ATRX)

Stock Price: $0.101 USD 0.011 (12.22%)
Updated Aug 11, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 1.10M
Revenue (ttm) 249,000
Net Income (ttm) -11.26M
Shares Out 10.87M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $0.101
Previous Close $0.090
Change ($) 0.011
Change (%) 12.22%
Day's Open 0.070
Day's Range 0.070 - 0.101
Day's Volume 12,451
52-Week Range 0.020 - 0.300

More Stats

Market Cap 1.10M
Enterprise Value 6.83M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 10.87M
Float 7.27M
EPS (basic) -1.17
EPS (diluted) -1.18
FCF / Share -0.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 40,932
Short Ratio 3.24
Short % of Float 3.93%
Beta 1.44
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.41
PB Ratio n/a
Revenue 249,000
Operating Income -10.08M
Net Income -11.26M
Free Cash Flow -7.04M
Net Cash -5.73M
Net Cash / Share -0.53
Gross Margin -63.05%
Operating Margin -4,048.59%
Profit Margin -5,124.50%
FCF Margin -2,828.19%
ROA -312.67%
ROE -2,977.88%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$400.00*
Low
400
Current: $0.101
High
400
Target: 400.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.250.08---0.502.124.222.242.46
Revenue Growth231.58%-----76.36%-49.85%88.6%-9.11%-
Gross Profit-0.16-0.21---0.502.124.222.242.46
Operating Income-11.32-15.80-6.09-0.76-1.11-3.52-0.37-7.88-35.00-29.53
Net Income-11.98-16.76-6.22-0.84-1.11-6.48-1.57-9.55-29.42-27.75
Shares Outstanding10.8410.849.8447.430.292.461.691.340.630.18
Earnings Per Share-1.24-1.64-0.63-0.02-3.80-5.10-0.90-7.10-46.50-158.00
Operating Cash Flow-8.74-9.61-1.26-0.52-0.74-4.780.29-4.39-16.12-16.80
Capital Expenditures--0.07----0.030.43--0.40
Free Cash Flow-8.74-9.69-1.26-0.52-0.74-4.780.32-3.96-16.12-17.21
Cash & Equivalents0.053.920.110.110.261.820.910.601.992.08
Total Debt5.33-1.910.69--1.621.45--
Net Cash / Debt-5.283.92-1.80-0.580.261.82-0.71-0.851.992.08
Assets0.425.146.186.190.269.227.747.4511.7529.44
Liabilities10.312.215.742.970.1713.5914.8113.0811.7112.27
Book Value-9.892.930.453.220.09-4.37-7.06-5.630.0417.17
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adhera Therapeutics, Inc.
Country United States
Employees 2
CEO Andrew Albert Kucharchuk

Stock Information

Ticker Symbol ATRX
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: ATRX

Description

Adhera Therapeutics, Inc., a specialty pharmaceutical company, engages in the development and commercialization of drug therapeutics for chronic and acute diseases in the United States. It markets Prestalia, a single-pill fixed dose combination of perindopril argenine, an ACE inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is headquartered in Wake Forest, North Carolina.